|
Getting your Trinity Audio player ready...
|
Aug. 14, 2026 — Investor attention continues to focus on microcap stocks, small-cap earnings, artificial intelligence, cybersecurity, biotechnology, Alzheimer’s drug development and high-growth technology, with Kartoon Studios (NYSE American: TOON), Cycurion (NASDAQ: CYCU), SurgePays (NASDAQ: SURG), MDxHealth (NASDAQ: MDXH) and IGC Pharma (NYSE American: IGC) presenting several developing catalysts.
Kartoon Studios, Inc. (NYSE American: TOON) reported Q2 2026 revenue of approximately $5.8 million, net income of $27.0 million and EPS of approximately $0.38, with net income primarily reflecting a $39.2 million non-recurring litigation settlement gain. TOON ended the quarter with $40.5 million in cash and marketable securities and no long-term debt, while approximately $39.2 million of additional settlement proceeds remain in escrow, subject to legal fees and distributions. Total expenses declined 32% year-over-year as the company shifts toward owned intellectual property and higher-margin franchise monetization. Major catalysts include an Amazon Prime Video (NASDAQ: AMZN) agreement to launch Hundred Acre Wood on February 18, 2027, the Stan Lee Universe, and former Activision Blizzard licensing executive Brooke Bacon leading consumer products and licensing.
Cycurion, Inc. (NASDAQ: CYCU) is an IT cybersecurity and artificial intelligence solutions provider serving government, healthcare and corporate customers. The company’s AI-enhanced ARx cybersecurity platform, combined with its program management and business-continuity capabilities, positions CYCU within growing demand for AI cybersecurity, government technology and digital infrastructure protection.
SurgePays, Inc. (NASDAQ: SURG) reported a significant Q2 improvement, with revenue increasing 40.7% year-over-year to $16.20 million and first-half revenue climbing 45.7% to $32.19 million. The company returned to GAAP profitability with $1.29 million in net income, or $0.05 per share. Operating income improved by approximately $10.3 million year-over-year, swinging from a $6.8 million operating loss to $3.5 million in operating income, while management expects a seventh consecutive quarter of sequential revenue growth.
MDxHealth SA (NASDAQ: MDXH), a urology-focused precision diagnostics company, reported Q2 revenue of $27.2 million, up 16% year-over-year and approximately $3.3 million sequentially from Q1. The company reported an operating loss of $5.1 million compared with $1.5 million in the prior-year quarter, primarily reflecting higher operating expenses associated with the ExoDx acquisition, as MDxHealth expands its position in precision diagnostics and urological cancer testing.
IGC Pharma, Inc. (NYSE American: IGC) is strengthening its regulatory, biostatistical, pharmaceutical-development and AI-enabled data science capabilities as lead Alzheimer’s drug candidate IGC-AD1 advances toward expected Phase 2 topline results in Q4 2026. The upcoming clinical data represents an important milestone as the company develops potential treatments targeting Alzheimer’s disease and neurodegenerative disorders.
With catalysts spanning Q2 earnings, Amazon streaming, artificial intelligence, cybersecurity, telecommunications growth, precision diagnostics and Phase 2 Alzheimer’s clinical trials, TOON, CYCU, SURG, MDXH and IGC are among the microcap stocks investors may be watching as the second half of 2026 progresses.